1. Scrip
  2. >>Business

Canaan Has Capital For Start-Ups With Eye On New Twists On Traditional Modalities In Pharma

 
• By Jessica Merrill

VC partner Colleen Cuffaro talked to Scrip about how the investment firm plans to direct investment in biopharma and raising capital in a challenging environment.

money bags
Canaan has raised capital for a new fund to invest in biopharma • Source: Shutterstock

Canaan Partners will invest $650m in health care and technology start-ups as part of a new, oversubscribed fund called Canaan XIII, the VC firm announced on 6 April. About 35% of the money, which will be dedicated to entrepreneurs seeking seed and series A financing, will be devoted to investment in biopharma.

An additional $200m of commitments is available to existing portfolio companies across all of Canaan’s active funds, with a similar...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.